ITM, a Munich, Germany-based radiopharmaceutical biotech company, raised €188M in funding.
The round was led by Temasek with participation from funds managed by BlackRock, Qatar Investment Authority (QIA), ATHOS and Carbyne.
Led by CEO Steffen Schuster, ITM is a radiopharmaceutical biotech company that is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors.
The company intends to use the funds to advance and expand its radiopharmaceutical pipeline, foster its development platform and prepare commercial readiness for the potential market launch of its phase III lead candidate, ITM-11 (n.c.a. 177Lu-edotreotide) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Funds will also enable expansion of manufacturing capabilities for the production of alpha- and beta-emitting radioisotopes, including Lutetium-177(177Lu) and Actinium-225(225Ac).
FinSMEs
06/06/2024